Sukuba (Pemetrexed) is fundamentally used to address the systemic challenge of advanced primary cancers of the chest, including non-squamous non-small cell lung cancer (NSCLC) and unresectable malignant pleural mesothelioma (MPM), and is considered relevant in conditions where these symptoms may intensify temporarily. The treatment is relevant in contexts involving heightened systemic burden.

This treatment is commonly used to help with managing symptoms related to tumor burden, such as severe, chronic pain and respiratory distress (shortness of breath). In situations where patients experience these disruptive symptom manifestations, the treatment provides supportive relief that eases the overall symptom load and may help patients cope more steadily with difficult symptomatic periods.

“This continuous intervention is relevant when symptoms and functional capacity have been temporarily stabilized.”

The treatment strategy is relevant in clinical scenarios where the drug helps support disease stabilization or tumor shrinkage, and it may be part of symptomatic management in an ongoing maintenance phase following initial aggressive chemotherapy. This continuous intervention contributes to easing the overall symptom load and moderating the progression of the condition.

---

Quick Fact: Support for symptoms related to physical discomfort

The medication supports patients during episodes of heightened discomfort that are linked to organ-specific functional stress, helping to ease the pressure and associated pain.

This section outlines the official population eligibility for Sukuba (Pemetrexed) as defined by government regulatory documents, detailing who is allowed, restricted, or prohibited from using the medicine.

Eligibility Scope

Status	Population/Condition	Regulatory Classification
Allowed	Adults (ge 18 years)	Standard use
	CrCl ge 45 mL/min	Mandatory minimum
	Adequate baseline blood counts	Conditional use
Not Recommended	Pediatric patients (under 18)	Use not established
	Severe hepatic impairment	Use not studied
Contraindicated	Pregnancy and Breastfeeding	Absolute prohibition
	Known hypersensitivity to Pemetrexed	Absolute prohibition

---

Official Eligibility Statements

• The medicine is contraindicated for women who are pregnant or breastfeeding, and for patients with a known severe hypersensitivity to the active ingredient. Use is also contraindicated with the concomitant yellow fever vaccine.
• Administration is not recommended for patients whose Creatinine Clearance (CrCl) is less than 45 mL/min, due to the risk of increased toxicity.
• Use is conditional upon mandatory premedication with oral folic acid and intramuscular vitamin B12, and meeting minimum hematologic thresholds (ANC ge 1,500 cells/mm^3 and Platelets ge 100,000 cells/mm^3) before each cycle.
• The drug is approved for use only in adults; safety and effectiveness have not been established in children and adolescents.

The official regulatory documentation defines eligibility through these strict prohibitions and physiological preconditions, ensuring the medicine is used only within its established safety boundaries.

Interactions with other medicines and products

Sukuba's interaction profile is primarily defined by its clearance through specific metabolic enzymes and transport systems in the body. Concomitant use with other medications or products can alter the amount of Sukuba in the bloodstream, which may necessitate specific precautions as detailed in official regulatory documents.

Key Interaction Categories

The most significant interactions involve medicines that are known to affect the body’s primary clearance pathways for Sukuba. These are officially classified into the following functional groups:

• Strong Inhibitors of Clearance: Co-administration with strong inhibitors of the main metabolic enzyme (e.g., Cytochrome P450 3A4) or transport system (e.g., P-glycoprotein) is expected to significantly increase the systemic exposure of Sukuba. Official guidance often mandates avoiding these combinations or implementing very specific management strategies.
• Strong Inducers of Clearance: Co-administration with strong inducers of the primary metabolic enzyme can lead to a clinically significant decrease in Sukuba exposure. The official documentation requires avoiding these combinations due to the potential for reduced therapeutic effect.
• Moderate Inhibitors/Inducers: Medicines that moderately affect the clearance pathways may also require specific management or monitoring as directed by the prescribing information.

Practical Implications

Regulatory agencies require that the official product labeling provide specific instructions for managing these interactions. These instructions define the constraints for prescribing Sukuba alongside other medicines, emphasizing the need to follow documented guidance regarding co-administration to maintain safe and appropriate exposure.

How Sukuba Works: Mechanism of Action

The mechanism of Pemetrexed (Sukuba) involves the drug's characteristic action to disrupt the core metabolic processes required for the formation of new genetic material.

Multi-Target Inhibition and Nucleotide Starvation

As a multitargeted antifolate, Pemetrexed is actively transported into the cell where it is metabolically activated into its polyglutamated form. This activated form functions as a competitive inhibitor against three key enzymes: Thymidylate Synthase (TS), GAR Formyltransferase (GARFT), and Dihydrofolate Reductase (DHFR). By simultaneously inhibiting these targets, the drug profoundly disrupts the folate metabolic pathway, causing a combined depletion of both purine and pyrimidine precursors necessary for DNA and RNA synthesis.

Inducing Cell Cycle Arrest and Apoptosis

The resulting lack of available nucleotide precursors leads to replication stress and irreparable DNA damage in cells that are actively dividing. This cellular failure triggers intrinsic signaling pathways that culminate in apoptosis (programmed cell death). The physiological consequence is the preferential suppression of proliferation in cellular populations with high, sustained division rates throughout the body.

Sukuba (Pemetrexed) is administered exclusively as an intravenous (IV) infusion under the supervision of a qualified physician. Its use is defined by precise, standardized instructions documented in regulatory prescribing information.

Administration Regimen

The dose of Sukuba is 500 mg/m^2, which is calculated based on the patient's body surface area. The drug is given on Day 1 of a 21-day cycle, meaning administration occurs once every three weeks. The infusion time for the drug is strictly defined, requiring administration over a 10-minute duration.

Essential Administration Requirements

Specific procedural steps are mandatory for the proper use of Pemetrexed. The drug must first be reconstituted and diluted using 0.9% Sodium Chloride Injection; calcium-containing solutions must be avoided during this preparation.

Co-medication Protocol	Co-medication	Administration Schedule
Folic Acid (Oral)	Daily, beginning at least seven days before the first dose.
Vitamin B12 (IM)	One week prior to the first dose, and then repeated every three cycles.
Dexamethasone (Oral)	Twice daily for three consecutive days (before, during, and after administration).

Use Context Constraints

Before each 21-day cycle, the patient's Creatinine Clearance (CrCl) must be assessed, as Pemetrexed is not recommended for administration if the CrCl is below 45 mL/min. Treatment duration is typically limited to six cycles for initial therapy or continues until disease progression in maintenance settings.

Research Evidence / Overview of Studies for Sukuba (Pemetrexed)

---

Evidence for Use in Malignant Pleural Mesothelioma (MPM)

Research examining Pemetrexed in Malignant Pleural Mesothelioma (MPM) largely centers on a definitive, large-scale Randomized Controlled Trial (RCT). This pivotal study was conducted to assess Pemetrexed combined with cisplatin in adult patients with unresectable MPM who had not previously received chemotherapy. The study monitored key outcomes such as Overall Survival (OS) and Progression-Free Survival (PFS), which are measures of time related to disease progression. Research describes that the combination regimen was associated with longer measurements for both OS and PFS compared to the control group. These findings were observed under the study's design, which required concurrent co-administration of supplements.

---

Evidence for Use in Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Initial (First-Line) Treatment Studies

Research for this setting includes multiple large Randomized Controlled Trials (RCTs) that research examined Pemetrexed combined with platinum-based therapy against other standard two-drug chemotherapy combinations. These trials were specific to the non-squamous histology of the disease, as data show patterns related to different outcomes in patients with the squamous subtype. Studies measured long-term endpoints like Overall Survival (OS) and the initial Objective Tumor Response Rate (ORR), exploring whether this combination was associated with measurements comparable to other regimens.

Maintenance Treatment Studies

Research examined Pemetrexed in the maintenance setting through a large Randomized, Double-Blind, Placebo-Controlled Phase III RCT. The study monitored Progression-Free Survival (PFS) and Overall Survival (OS). The pivotal maintenance study reported that the measurements for the time without disease progression were longer when Pemetrexed maintenance was used, compared to the placebo group.

---

What Research Gaps Remain Uncertain

In general, results apply only to the populations studied. Key trials often excluded individuals who had significant organ problems or a poor functional status, meaning data for certain groups remain insufficient. Research is ongoing to determine how Pemetrexed performs when combined with newer forms of therapy, such as immunotherapies and targeted agents, as comparative evidence is lacking in some of these newer treatment sequences. Studies are still exploring whether specific molecular changes within the tumor could better predict which individual patients were associated with greater differences in measured outcomes.

Key Studies & References

1. Maintenance Pemetrexed Versus Placebo After Induction Cisplatin Plus Pemetrexed for Advanced Non-Squamous Non-Small-Cell Lung Cancer (PARAMOUNT): A Phase 3, Double-Blind, Randomised, Controlled Trial

Common questions about Sukuba (FAQ)

Q: Is Sukuba similar to other common medicines for the same condition?

Official documents classify the active ingredient in Sukuba as a multitargeted antifolate and antineoplastic agent. This classification indicates that its mechanism of action is unique, as it is described as inhibiting three key metabolic enzymes simultaneously, which defines its action relative to other available medicines.

Q: Are there any common vitamins or supplements that interact with Sukuba?

Official information mandates the use of oral folic acid and intramuscular vitamin B12 supplements to reduce the risk of certain toxicities. The official label notes the potential for increased exposure when co-administered with certain non-steroidal anti-inflammatory drugs (NSAIDs) with a long elimination half-life.

Q: Can Sukuba be taken with pain relievers like ibuprofen or Tylenol?

Official documents state that patients with certain kidney function levels are typically restricted from taking NSAIDs, such as ibuprofen, for a specified period before, during, and after administration. Acetaminophen (the active ingredient in Tylenol) is not explicitly listed in these specific NSAID warnings.

Q: Is it normal to feel a bit nauseous when first starting Sukuba?

Nausea is documented in the official safety profile as a very common adverse reaction, meaning it has been reported in more than one in ten patients. Regulatory documents state the frequency of this event but do not specify if it is more frequent only at the very start of the treatment.

Q: What is the difference between Sukuba and the older medicine, [Similar Drug Name]?

The official product information describes the active ingredient as a multitargeted antifolate. Its characteristic action is defined by its ability to simultaneously inhibit three key metabolic enzymes (Thymidylate Synthase, GAR Formyltransferase, and Dihydrofolate Reductase) in the cell.

Q: Is it okay to take herbal remedies like St. John's Wort with Sukuba?

Regulatory documents caution against co-administration with other medicines that are known to strongly affect the body's primary metabolic and transport systems. Since many herbal remedies can influence these systems, official guidance notes the need for careful review of co-administered substances.

Q: If I feel better, can I just stop using Sukuba?

Official regulatory documents define the duration of Sukuba treatment. The standard regimen is typically limited to a specific number of cycles for initial therapy or continues until disease progression in a maintenance setting, as outlined in the official use conditions.

Q: Are there any long-term side effects associated with Sukuba use?

Official documents list documented adverse reactions by frequency, covering all reported effects from clinical trials and post-marketing experience, including serious events. The official safety profile describes all documented adverse reactions by frequency but does not specifically categorize these events as strictly 'short-term' or 'long-term' based on duration after therapy.

Q: What is the shelf life of the medicine?

According to official regulatory documents, the shelf life for the unopened vial of the lyophilized powder is documented as three years when stored correctly. The stability and expiration date for the solution once it has been mixed for infusion are different.

Q: Will Sukuba cure my condition, or just manage the symptoms?

Official product information describes the drug's purpose as a chemotherapy agent aimed at inhibiting cell division and suppressing tumor proliferation. The drug’s documented action is consistent with the goals of disease control and management.

Q: Is Sukuba a controlled substance or addictive?

Sukuba (Pemetrexed) is officially classified by regulatory authorities as a prescription-only antineoplastic agent. It is not classified or listed as a federally controlled substance.

Q: Does Sukuba have any known effects on fertility?

Official regulatory documents note that the therapy may impair fertility in males of reproductive potential. Official documents note that patients may wish to review any concerns about future fertility with their healthcare provider.

Q: Does Sukuba interact with alcohol?

Official regulatory documents do not list alcohol as a formal pharmacokinetic interaction. However, some clinical practice guidelines indicate that alcohol intake may be restricted due to the potential for increasing certain common side effects, such as gastrointestinal toxicity.

Q: Does Sukuba cause changes in mood or sleep patterns?

Official adverse reaction lists document side effects that include trouble sleeping (insomnia) and mood changes or feelings of sadness/emptiness in some frequency categories. This information is available in the medicine's safety profile.

Q: How long after taking Sukuba can I drive or operate machinery?

Official documents note that specific studies on the effect of the medicine on the ability to drive and operate machines have not been performed. However, because fatigue is a reported side effect, official documents note that patients should be aware of this potential event.

Q: Is Sukuba safe to use if I have high blood pressure?

Official prescribing information advises that patients with pre-existing conditions like high blood pressure should discuss their medical history with their physician. Official information suggests that patients with high blood pressure may require special monitoring during treatment.

Q: Is Sukuba ever prescribed for conditions other than its main approved use?

Official regulatory documents define the medicine's approved use based on demonstrated safety and effectiveness in clinical trials. They do not describe or provide information for use outside of these specific approved indications.

Q: Why do official documents mention that certain foods should be avoided with Sukuba?

The specific constraint mentioned in official documents is the chemical incompatibility of the powdered drug with calcium-containing solutions used by the physician for reconstitution and dilution. This constraint is related to the mixing process and is not a restriction on patient foods.

Q: What should I do if I accidentally take too much Sukuba?

Official regulatory documents provide information regarding the management of a potential overdose, which may involve specific medical interventions as outlined in the prescribing information.

Q: Is Sukuba safe for people who have a history of heart problems?

Official documents state that the use requires careful consideration in patients with pre-existing cardiovascular risk factors. The safety profile also lists certain cardiac issues (such as arrhythmia or cardiac failure) as documented adverse events in some frequency categories.

Q: What does 'use conditions' mean in the context of Sukuba?

In the context of official drug labeling, 'use conditions' refers to the constraints, preparations, and requirements mandated by the regulatory authority for safe and appropriate administration. Examples include the required co-medications (Folic Acid/ B12) and meeting minimum kidney function limits.

Q: Does Sukuba interact with birth control pills?

Official regulatory documents note that the medicine can have genetically damaging effects. Official documents state that women of childbearing potential are required to use effective contraception during treatment and for a specified period afterward.

Q: What is the difference between an 'adverse event' and a 'side effect'?

According to authoritative sources, an 'adverse event' is generally defined as any unwanted or unfavorable medical experience that occurs during treatment. A 'side effect' usually refers to a known or expected undesirable effect that is specifically documented in the medicine's official safety profile.

The storage and disposal requirements for Sukuba (Pemetrexed) are dictated by its formulation and classification as a hazardous drug.

Storage Conditions

Item	Official Regulatory Statement
Temperature requirements	Powder: Controlled Room Temperature (20 C to 25 C). Solution: Controlled Refrigerated Temperature (2 C to 8 C).
Stability after mixing	Reconstituted/Diluted: Stable for no longer than 24 hours when stored refrigerated (2 C to 8 C).
Handling constraints	Do not use calcium-containing diluents. The product must be stored out of the reach and sight of children.

Disposal Instructions

Sukuba is classified as a hazardous (cytotoxic) drug supplied in single-dose vials. Any unused portion must be discarded. Disposal must follow applicable special handling and disposal procedures for anticancer agents and comply with local and national hazardous waste regulations. Unused medicine must not be placed in household trash or disposed of through wastewater.